Trauma to the cavernous nerve is a known cause of erectile dysfunction, with lengthy and often incomplete recovery. Using rat models, we have previously shown that injury to the cavernous nerves or ligation of pudendal arteries causes a significant decrease of neuronal nitric oxide synthase (nNOS) in the dorsal nerve of the penis and intracavernosal tissue as well as loss of erectile response to neurostimulation. Intracavernous injection of vascular endothelial growth factor or brain-derived neurotrophic factor facilitates the recovery of nNOS and erectile function. Studies are underway to elucidate the molecular mechanism of cavernous nerve regeneration and the potential of using growth factors to enhance the recovery of erectile function in patients after radical pelvic surgery.
Introduction
Through the release of nitric oxide from their nerve terminals, the cavernous nerves serve an important function in the initiation and regulation of penile erection. Injury to the cavernous nerves is common in radical pelvic surgeries such as prostatectomy, cystectomy, and proctocolectomy. With nerve-sparing operations, a higher percentage of patients are now able to regain erectile function. However, the recovery process is slow and only about 15% of men who undergo a radical prostatectomy can achieve an erection sufficient for intercourse in the first six postoperative months. 1 Because nitric oxide is produced by neuronal nitric oxide synthase (nNOS) in the cavernous nerve, this article will discuss the down-and up-regulation of nNOS in nerve injury and recovery, as well as the potential role of growth factors in facilitating cavernous nerve regeneration.
Two sets of nerves innervate the penis: the somatic and the autonomic. Of the autonomic nerves, the cavernous nerve comprises mostly parasympathetic fibers, and thus trauma to the cavernous nerve is selective to parasympathetic innervation of the penis. As an injury ensues, the signal is sensed by nearby Schwann cells, which then produce and release neurotrophins that promote regeneration of the injured axon. [2] [3] [4] Four neurotrophins have been characterized in mammals: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). Although similar in sequence and structure, different neurotrophins play distinctive roles during neuronal development and regeneration. Vascular endothelial growth factor (VEGF) was originally discovered and identified as an endothelial-specific growth factor involved in the formation of new blood vessels (angiogenesis). However, it is now increasingly evident that VEGF also possesses neurotrophic properties, as it has been shown to stimulate the survival, axonal outgrowth, and regeneration of neurons. 5, 6 Jung et al 7 created a rat model to study changes in nNOS-containing nerve fibers. In this model, rats were divided into four groups: (1) sham operation; (2) unilateral neurotomy of a 5-mm segment of the cavernous nerve; (3) unilateral neurotomy with growth hormone therapy; and (4) bilateral neurotomy. Electrostimulation of the intact cavernous nerve or pelvic ganglion above the neurotomy site was conducted 1, 3, and 6 months following the procedure. One month postneurotomy, significant decreases in nNOS-containing nerve fibers of the dorsal and intracavernosal nerves were observed on the side of neurotomy in both unilateral and bilateral neurotomy groups. These groups exhibited lower mRNA expression of nNOS, IGF-I, and TGF-b2 and higher mRNA expression of eNOS and VEGF 189 .
At 3 months, the number of nNOS fibers in the unilateral neurotomy group increased only slightly, whereas the growth hormone-treated group displayed a significant increase. Messenger RNA expression of nNOS, IGF-I, and TGF-b2 showed a significant increase as early as 3 months. After bilateral neurotomy, the number of nNOS-containing fibers in the dorsal and intracavernosal nerves decreased significantly and remained low after 6 months. Pelvic ganglion stimulation could not elicit any erectile response in this group. In the unilateral neurotomy group at 6 months, more nNOS neurons in the pelvic ganglia were discovered on the intact side compared with the side of the neurotomy, demonstrating regeneration from pelvic ganglion neurons on the intact side. In addition, electrostimulation in the unilateral neurotomy group revealed a greater maximum intracavernosal pressure and a shorter latency period at 6 months vs 1 month. These findings suggest that IGF-I and TGF-b2 may contribute to the regeneration of nNOS-containing fibers and that exogenous growth hormone may assist in nerve growth.
The effect of BDNF on neural recovery and erectile function after cavernous nerve injury has also been studied in rats. 8 The animals underwent either a sham operation or bilateral cavernous nerve freezing, and intracavernous injection of adenoassociated virus (AAV)-LacZ (control) or AAV-BDNF. In the AAV-BDNF-treated group, mean maximal intracavernous pressure was significantly higher than in the AAV-LacZ-treated group at 4 weeks (58.5 vs 28.4 cmH 2 O) and at 8 weeks (61.3 vs 37.7 cmH 2 O). Furthermore, at each time point, the AAV-BDNF-treated group contained significantly more nNOS-positive nerve fibers in the dorsal nerves and cavernous tissue than in the AAV-LacZtreated group. The percentage of nNOS-positive neurons in the major pelvic ganglia was also significantly greater. Therefore, intracavernous injection of AAV-BDNF may prevent the degeneration of neuronal nNOS neurons in the major pelvic ganglia and may facilitate the regeneration of nNOScontaining nerve fibers in penile tissue, thus enhancing recovery of erectile function following bilateral cavernous nerve injury.
The effect of intracavernous injection of VEGF on erectile function was studied in a rat model of traumatic arteriogenic erectile dysfunction (ED). 9 Rats underwent bilateral ligation of the internal iliac arteries or a sham operation. Immediately after arterial ligation, none of the rats had an erectile response to neurostimulation. Significant recovery of erectile function occurred 1-6 weeks after the procedure in VEGF-treated rats. A reduction in nNOS fibers in the dorsal or intracavernous nerves was noted after 1 week. Treatment with VEGF was associated with a moderate recovery of nNOS fibers. Partial recovery of the induced atrophy of myelinated and nonmyelinated nerve fibers in dorsal nerves was observed in VEGF-treated rats. Interestingly, VEGF-treated rats showed hypertrophy and hyperplasia of the endothelial cells, especially those lining the small capillaries. Together, these results indicate that intracavernous injection of VEGF soon after arterial ligation facilitates the recovery of erectile function partly through recovery of nNOScontaining nerves.
In addition to in vivo studies in rats undergoing injury to cavernous nerve or internal pudendal arterial ligation, we have also established an in vitro model of pelvic ganglion culture (Lin et al 10 ) . Among several growth factors tested, we have found that both BDNF and VEGF facilitated the outgrowth of axons that stained positive for nNOS. Both the in vivo and in vitro studies mentioned above demonstrated the beneficial role of growth factors in neural regeneration and up-regulation of nNOS, as well as in the recovery of erectile function. An important unanswered question is whether intracavernous therapy with growth factors has clinical potential as a future treatment for ED.
